Comparison 6. Secondary malignancies (previously untreated patients).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 AML/MDS	4	1023	Risk Ratio (M‐H, Random, 95% CI)	2.87 [0.70, 11.75]
2 AML/MDS/ rituximab‐containing regimen	4	1023	Risk Ratio (M‐H, Random, 95% CI)	2.87 [0.70, 11.75]
2.1 Rituximab in both arms	1	134	Risk Ratio (M‐H, Random, 95% CI)	4.85 [0.58, 40.44]
2.2 No rituximab in both arms	3	889	Risk Ratio (M‐H, Random, 95% CI)	2.61 [0.38, 17.93]
3 Solid cancer	3	701	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.25, 5.77]
4 Solid cancer/ rituximab‐containing regimen	3	701	Risk Ratio (M‐H, Random, 95% CI)	1.20 [0.25, 5.77]
4.1 Rituximab in both arms	1	134	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.03, 3.03]
4.2 No rituximab in both arms	2	567	Risk Ratio (M‐H, Random, 95% CI)	2.44 [0.20, 29.93]